Rene Y Choi1, Mark Asquith2, James T Rosenbaum1,2,3. 1. Department of Ophthalmology, Casey Eye Institute. 2. Division of Arthritis and Rheumatic Diseases, Department of Ophthalmology, Oregon Health and Science University. 3. Legacy Devers Eye Institute, Portland, Oregon, USA.
Abstract
PURPOSE OF REVIEW: The intestinal microbiome is thought to play a role in the pathogenesis of inflammatory bowel disease (IBD). There are many shared clinical manifestations between IBD and spondyloarthritis (SpA), of which the most common are peripheral arthritis and uveitis. Clinical overlap along with similar genetics between these diseases suggests a possible shared pathogenetic mechanism, which might center on the intestinal microbiota. In this review, we discuss the available evidence that SpA is a microbiome-driven disease and indicate how SpA-associated uveitis could be tied to gut dysbiosis. We conclude by discussing different treatment paradigms targeting the intestinal microbiome for SpA. RECENT FINDINGS: Recent studies support the growing evidence of the intestinal microbiome as a crucial player in SpA disease pathogenesis. There is emerging evidence that the gut microbiome may play a causative role in uveitis. SUMMARY: The field is beginning to discover a new level of understanding how the intestinal microbiome is involved in SpA. Treatment methods to alter intestinal microbiota to treat SpA-related diseases are still in its infancy.
PURPOSE OF REVIEW: The intestinal microbiome is thought to play a role in the pathogenesis of inflammatory bowel disease (IBD). There are many shared clinical manifestations between IBD and spondyloarthritis (SpA), of which the most common are peripheral arthritis and uveitis. Clinical overlap along with similar genetics between these diseases suggests a possible shared pathogenetic mechanism, which might center on the intestinal microbiota. In this review, we discuss the available evidence that SpA is a microbiome-driven disease and indicate how SpA-associated uveitis could be tied to gut dysbiosis. We conclude by discussing different treatment paradigms targeting the intestinal microbiome for SpA. RECENT FINDINGS: Recent studies support the growing evidence of the intestinal microbiome as a crucial player in SpA disease pathogenesis. There is emerging evidence that the gut microbiome may play a causative role in uveitis. SUMMARY: The field is beginning to discover a new level of understanding how the intestinal microbiome is involved in SpA. Treatment methods to alter intestinal microbiota to treat SpA-related diseases are still in its infancy.
Authors: Carmen Antía Rodríguez-Fernández; Manuel Busto Iglesias; Begoña de Domingo; Kelly Conde-Pérez; Juan A Vallejo; Lorena Rodríguez-Martínez; Miguel González-Barcia; Victor Llorenç; Cristina Mondelo-Garcia; Margarita Poza; Anxo Fernández-Ferreiro Journal: Int J Mol Sci Date: 2022-06-24 Impact factor: 6.208
Authors: Jonas Sagard; Tor Olofsson; Elisabeth Mogard; Jan Marsal; Kristofer Andréasson; Mats Geijer; Lars Erik Kristensen; Elisabet Lindqvist; Johan K Wallman Journal: Arthritis Res Ther Date: 2022-02-12 Impact factor: 5.156
Authors: Kevin L Winthrop; Michael E Weinblatt; Joan Bathon; Gerd R Burmester; Philip J Mease; Leslie Crofford; Vivian Bykerk; Maxime Dougados; James Todd Rosenbaum; Xavier Mariette; Joachim Sieper; Fritz Melchers; Bruce N Cronstein; Ferry C Breedveld; Joachim Kalden; Josef S Smolen; Daniel Furst Journal: Ann Rheum Dis Date: 2019-10-29 Impact factor: 19.103